278 related articles for article (PubMed ID: 12738593)
1. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.
Mitchison DA
Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593
[No Abstract] [Full Text] [Related]
2. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
[TBL] [Abstract][Full Text] [Related]
3. Rifapentine for the treatment of tuberculosis: is it all it can be?
Gordin FM
Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Roy V; Tekur U; Chopra K
Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
[TBL] [Abstract][Full Text] [Related]
5. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
[TBL] [Abstract][Full Text] [Related]
7. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
8. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
[TBL] [Abstract][Full Text] [Related]
10. [Intensive chemotherapy of pulmonary tuberculosis].
Shesterina MV; Gavrilenko VS; Tarasova EF; Sokolova GV; Tregubov IuG
Probl Tuberk; 1980 Jul; (7):20-22. PubMed ID: 6997865
[No Abstract] [Full Text] [Related]
11. Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
Cruz AT; Starke JR
Pediatr Infect Dis J; 2016 Jul; 35(7):811-3. PubMed ID: 27088582
[TBL] [Abstract][Full Text] [Related]
12. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
Tam CM; Chan SL; Lam CW; Leung CC; Kam KM; Morris JS; Mitchison DA
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1726-33. PubMed ID: 9620898
[TBL] [Abstract][Full Text] [Related]
13. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
[TBL] [Abstract][Full Text] [Related]
14. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
15. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
[No Abstract] [Full Text] [Related]
16. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
17. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
Khodashova ML; Iuditskiĭ MV; Semenova OV
Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
[TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
[TBL] [Abstract][Full Text] [Related]
19. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
[No Abstract] [Full Text] [Related]
20. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
Ul-Ain Q; Sharma S; Khuller GK
Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
